Patrick E O'Brien

US Patent:

6906092, Jun 14, 2005

Filed:

Jun 25, 2003

Appl. No.:

10/603677

Inventors:

Patrick Michael O'Brien - Stockbridge MI, US
Joseph Armand Picard - Canton MI, US
Drago Robert Sliskovic - Saline MI, US
Andrew David White - Pinckney MI, US

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K031/40

US Classification:

514411, 514443, 514444, 514468, 514601, 514602, 514603, 514604, 514605

Abstract:

The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

US Patent:

7395275, Jul 1, 2008

Filed:

Feb 14, 2000

Appl. No.:

09/503671

Inventors:

Brent C. Parent - Holland OH, US
Aaron J. Roth - Sylvania OH, US
Patrick O'Brien - Maumee OH, US

Assignee:

Dana Automotive Systems Group, LLC - Toledo OH

International Classification:

G06F 17/00

US Classification:

7071041, 705 7

Abstract:

A system for managing assets, and facilitating electronic commerce respecting the assets includes a computerized database for storing asset profiles for a plurality of assets. The asset profiles, each include an asset specification and a bid definition. The asset specification includes maintenance history data for the asset and the bid definition outlines the bounds for one of sale, rental or lease of the asset. Users of the system may search the database remotely over the Internet for desired assets, and retrieve detailed information, such as maintenance history, and then bid on the asset for purchase, rental, or lease. Users can also add their own assets to the database for search by others. The system also includes a fantasy fleet feature for conducting “what if” analyses of a simulated fleet containing existing assets and proposed assets.

US Patent:

20020077944, Jun 20, 2002

Filed:

Nov 14, 2001

Appl. No.:

09/990911

Inventors:

J. Bly - Maumee OH, US
David Spieldenner - Gibsonburg OH, US
Aaron Roth - Sylvania OH, US
Patrick O'Brien - Maumee OH, US
Andrew Suhy - West New York NJ, US
Brent Parent - Holland OH, US

International Classification:

G06F017/60

US Classification:

705/035000

Abstract:

A database is configured and information associated with a plurality of assets is stored in the database. The system automatically analyzes the information in accordance with a set of pre-defined conditions. When a pre-defined condition is met, the subsystem recommends asset disposition using a hierarchy of disposition options, and the conditions and the options are selected to reduce expense and to maximize the return on investment for the asset user. The hierarchy of options are typically manually checked and confirmed, and a rejection of the hierarchy of options generates feedback with the system modifying as appropriate the availability of future options.

US Patent:

20020082966, Jun 27, 2002

Filed:

Nov 26, 2001

Appl. No.:

09/995374

Inventors:

Patrick O'Brien - Maumee OH, US
J. Bly - Maumee OH, US
Aaron Roth - Sylvania OH, US

Assignee:

Dana Commercial Credit Corporation

International Classification:

G06F017/60

US Classification:

705/036000

Abstract:

A computer based system that automatically gathers and analyzes relating to the procurement and utilization of a plurality of such assets, such as a fleet of industrial equipment, so as to maximize productivity and to reduce operating costs and administrative burdens by benchmarking relevant information. Benchmarking asset related data can be done on a company-wide or even industry-wide basis. The system is capable of benchmarking many different characteristics relating to assets. Industry-wide benchmarking can facilitate the determination of “best practices” for an entire industry. The system provides an analyst with a significant level of flexibility with regards to the types of data being benchmarked, the processing applied in the form a benchmark heuristic by the system.

US Patent:

20020156071, Oct 24, 2002

Filed:

Feb 13, 2002

Appl. No.:

10/075431

Inventors:

Patrick O'Brien - Stockbridge MI, US
Drago Sliskovic - Saline MI, US

International Classification:

C07D417/02
C07D279/12
A61K031/541
A61K031/54

US Classification:

514/227500, 544/059000, 544/060000, 514/228200

Abstract:

Matrix metalloproteinase inhibitors are tricyclic sulfonamides of the Formula I or a pharmaceutically acceptable salt thereof, wherein Rand Rinclude hydrogen, alkyl, and substituted alkyl; Ris OH or NHOH; X is O or S(O); n is 0, 1, or 2; p is 0, 1, 2, or 3;— is absent or a bond; and the sulfur atom bearing (O)is bonded to the benzo ring at position a or position b.

US Patent:

20020169164, Nov 14, 2002

Filed:

Mar 27, 2002

Appl. No.:

10/108817

Inventors:

Patrick O'Brien - Stockbridge MI, US
Joseph Picard - canton MI, US
Drago Sliskovic - Saline MI, US

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K031/496
A61K031/403
A61K031/381
A61K031/352
A61K031/216

US Classification:

514/252130, 514/254080, 514/254110, 514/411000, 514/443000, 514/468000, 514/530000, 544/372000, 544/375000, 544/380000, 549/044000, 548/443000, 549/461000, 560/012000

Abstract:

Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.

US Patent:

20030032665, Feb 13, 2003

Filed:

Jun 4, 2002

Appl. No.:

10/162518

Inventors:

Patrick O'Brien - Stockbridge MI, US
Joseph Picard - Canton MI, US
Drago Sliskovic - Saline MI, US
Andrew White - Pinckney MI, US

International Classification:

A61K031/407
A61K031/405
A61K031/401
A61K031/4025

US Classification:

514/411000, 514/397000, 514/414000, 514/422000, 514/423000, 514/443000, 514/562000

Abstract:

The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

US Patent:

20040043984, Mar 4, 2004

Filed:

Aug 5, 2003

Appl. No.:

10/634288

Inventors:

Patrick O'Brien - Stockbridge MI, US

International Classification:

C07D487/02
A61K031/53
A61K031/525

US Classification:

514/210210, 514/243000, 514/251000, 514/264100, 544/184000, 544/257000, 544/279000, 544/350000, 514/249000

Abstract:

This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R, Q, Y, Y, Y, Y, R, R, and Rare as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.